RxDoctor Payments Data

Wen Guo, MD

Internal Medicine · Las Vegas, NVNPI 1437128030

Payments from drug & device makers

$2,029in general payments, 2019–2025

Across 34 payments — averaging $59.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$640
  • Abbott$530
  • Novo Nordisk$285
  • Lilly USA, LLC$219
  • Exact Sciences$141
  • Idorsia Pharmaceuticals US Inc$125
  • plus $88 from 2 others

What the payments were for

  • Food & beverage$2,029100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,029 in reported general payments places this provider in the 80th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$6,381
Medicare patients
21
Services billed
82

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol12$10,271
ProgesteroneProgesterone, Micronized20$1,484
Gabapentin22$465
Metformin Hcl ErMetformin Hcl31$380
Duloxetine Hcl11$304
Albuterol Sulfate HfaAlbuterol Sulfate14$294
Levothyroxine Sodium23$274
Potassium Chloride19$259
Metoprolol Succinate19$240
Rosuvastatin Calcium17$204
Amlodipine Besylate41$189
Losartan Potassium30$185
Atorvastatin Calcium27$170
Lisinopril12$158
Zolpidem Tartrate16$114

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$640$10,27112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →